Nighan Warren JR 4

4 · ANGIODYNAMICS INC · Filed Jul 22, 2026

AI-generated summary of this filing

Updated Jul 23, 2026

AngioDynamics (ANGO) SVP Nighan Warren Jr Receives Equity Awards

What Happened

Nighan Warren Jr., Senior VP, Quality and Regulatory at AngioDynamics, was granted equity awards on July 15, 2026: 17,966 restricted stock units (RSUs) and 17,966 performance rights. Both grants show $0.00 per share (awards, not open‑market trades).
The RSUs represent contingent rights to receive one share each; the performance rights are contingent on achieving performance goals and may convert to shares if targets are met. No cash changed hands.

Key Details

Transaction date: July 15, 2026; Form 4 filed July 22, 2026 (appears later than the typical 2-business‑day reporting window).
Grant amounts: 17,966 RSUs and 17,966 performance rights. Reported price: $0.00 (award).
Shares owned after transaction: not specified in the filing.
Footnote highlights:
- RSU vesting: 25% vest annually on July 15 in 2027, 2028, 2029 and 2030.
- Performance rights: each right can convert to one share; payout ranges from 0%–200% of target based on total shareholder return vs. peers over a three‑year period, with an additional +/-20% adjustment possible (aggregate potential up to 240% of target).
No indication of a 10b5-1 plan, tax withholding sale, or immediate sale of shares in this filing.

Context

These awards are compensation grants (A = Award/Grant), common for executives and typically intended for retention and performance alignment rather than signaling immediate insider buying or selling.
Performance rights are contingent and may never result in shares if performance metrics are not met; RSUs will convert to shares only as they vest.

Form 4

Period: 2026-07-15

SVP Quality and Regulatory

Transactions

Award
Common Stock
[F1]
2026-07-15+17,966→ 84,092 total
Award
Performance Right
[F2]
2026-07-15+17,966→ 17,966 total
→ Common Stock (17,966 underlying)

Footnotes (2)

[F1]The acquisition of 17,966 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,966 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
[F2]Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Signature

/s/ Lawrence T. Weiss, Attorney in Fact|2026-07-22

1 file